Top Page
CytoMed Therapeutics Limited
(NASDAQ:GDTC)
CytoMed Therapeutics Limited (GDTC) vs. SPDR S&P 500 ETF (SPY)
CytoMed Therapeutics Limited Business Overview & Revenue Model
CytoMed Therapeutics Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 52.01K | 290.56K | 0.00 | 84.18K | 44.92K |
| Gross Profit | -515.82K | 213.09K | -81.03K | 81.59K | 41.43K |
| EBITDA | -1.79M | -2.94M | -1.10M | -1.05M | -776.21K |
| Net Income | -1.88M | -3.13M | -2.27M | -1.53M | -1.47M |
Balance Sheet | |||||
| Total Assets | 7.38M | 9.37M | 3.88M | 4.50M | 2.88M |
| Cash, Cash Equivalents and Short-Term Investments | 3.64M | 6.82M | 1.18M | 1.87M | 885.27K |
| Total Debt | 339.20K | 448.02K | 3.13M | 2.41M | 2.25M |
| Total Liabilities | 750.59K | 852.28K | 3.45M | 2.58M | 2.52M |
| Stockholders Equity | 6.57M | 8.49M | 436.04K | 1.92M | 359.56K |
Cash Flow | |||||
| Free Cash Flow | -2.74M | -2.64M | -1.39M | -1.70M | -842.00K |
| Operating Cash Flow | -1.69M | -2.60M | -1.04M | ― | -641.69K |
| Investing Cash Flow | 494.59K | -2.14M | -351.60K | -609.05K | -387.57K |
| Financing Cash Flow | -33.36K | 8.27M | 793.25K | 3.09M | 1.42M |
CytoMed Therapeutics Limited Technical Analysis
CytoMed Therapeutics Limited Risk Analysis
CytoMed Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $105.84M | ― | -1738.36% | ― | -35.29% | 45.18% | |
48 Neutral | $23.58M | ― | -42.29% | ― | ― | -21.99% | |
47 Neutral | $8.23M | ― | -67.73% | ― | -2.06% | 64.86% | |
47 Neutral | $58.32M | ― | -53.78% | ― | ― | -5.42% | |
41 Neutral | $35.67M | ― | -312.77% | ― | ― | 61.18% | |
39 Underperform | $47.82M | ― | -322.57% | ― | ― | 3.39% |
CytoMed Therapeutics Limited Corporate Events
On October 2, 2025, CytoMed Therapeutics Limited announced a significant advancement in their research collaboration with The University of Texas, MD Anderson Cancer Center. The publication of their preclinical study highlights the potential of CytoMed’s allogeneic γδ T cell therapy for treating acute myeloid leukemia (AML), marking a promising step forward in developing ‘off-the-shelf’ immunotherapy solutions. This development is expected to pave the way for further clinical trials in Southeast Asia, potentially offering new treatment options for patients with limited alternatives, thereby strengthening CytoMed’s position in the biopharmaceutical industry.
On September 30, 2025, CytoMed Therapeutics Limited released its unaudited interim condensed consolidated financial statements for the six months ending June 30, 2025. The company reported a significant increase in revenue to S$155,887 compared to the previous year. However, the financial results also showed a comprehensive loss of S$2,269,263, reflecting ongoing challenges in the company’s financial performance. The announcement provides insights into the company’s operational challenges and financial health, which could impact its market positioning and stakeholder confidence.
On August 28, 2025, CytoMed Therapeutics Limited announced the successful expansion of clinical-scale natural killer (NK) cells from cord blood units, marking a significant step in their strategic reorganization. The company plans to establish a new cord blood-derived biotech under LongevityBank Pte Ltd, which will focus on autologous therapies, while CytoMed will continue to develop allogeneic therapies. This move aims to create new revenue streams and growth opportunities, leveraging their recent acquisition of a licensed cord blood bank in Malaysia. The acquisition provides access to valuable cord blood resources, enhancing CytoMed’s capabilities in developing therapeutics for autoimmune diseases and cancers. The company also plans to spin off LongevityBank as a standalone entity, further expanding its market presence.
On August 18, 2025, CytoMed Therapeutics Limited announced the initiation of an At-the-Market (ATM) offering program through a sales agreement with R.F. Lafferty & Co., Inc. This agreement allows CytoMed to sell ordinary shares worth up to $4,304,945, with the proceeds intended for general corporate purposes, including business diversification, development initiatives, and potential acquisitions. The announcement highlights the company’s strategic move to enhance its financial flexibility and explore growth opportunities, potentially impacting its market positioning and stakeholder interests.
On July 21, 2025, CytoMed Therapeutics Limited announced the successful completion of Dose Level 1 in its first-in-human Phase I dose-escalation clinical trial, known as the ANGELICA Trial. This trial evaluates the safety and tolerability of CTM-N2D, a novel allogeneic therapy using gamma delta T cells for treating advanced solid and haematological malignancies. The company is now proceeding to Dose Level 2, marking a significant milestone in its efforts to develop affordable cancer treatments. This advancement underscores CytoMed’s commitment to addressing the limitations of existing CAR-T therapies and enhancing its position in the biopharmaceutical industry.
On May 1, 2025, CytoMed Therapeutics Limited’s Compensation Committee and Board of Directors approved the issuance of ordinary shares to key executives as compensation for their continued service. This decision was formalized through supplemental agreements on July 1, 2025, highlighting the company’s commitment to retaining its leadership team, which could positively impact its operational stability and strategic positioning.
On June 26, 2025, CytoMed Therapeutics Limited held its annual shareholders meeting, where key resolutions were passed, including the adoption of the company’s audited financial statements for 2024 and the re-election of several directors. The meeting also approved the appointment of independent auditors for the upcoming fiscal year and authorized the issuance of new ordinary shares in connection with the company’s Nasdaq listing. These decisions are expected to strengthen the company’s governance and financial transparency, enhancing its position in the biotechnology sector.